Core Points - The announcement details the results of GMP compliance inspections for two pharmaceutical companies in Shaanxi Province, confirming that both companies meet the required standards [1] Group 1: Company Inspections - Shaanxi Baiyun Pharmaceutical Co., Ltd. was inspected from September 9 to September 12, 2025, and was found to be compliant with GMP requirements [1] - Shaanxi Jingyang Jinlan Skin Disease Research Institute and Shaanxi Kanghui Pharmaceutical Co., Ltd. were inspected on July 22, 2025, and from July 30 to August 1, 2025, respectively, and both were also found to be compliant with GMP requirements [1]

证券代码：603139 证券简称：康惠股份 公告编号：2025-073 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，陕西康惠制药股份有限公司（以下简称"公司"）获得陕西省药品监 督管理局许可，同意公司《药品生产许可证》（许可证编号：陕 20160073）法定 代表人由"王延岭"变更为"李红明"，企业负责人由"王延岭"变更为"WANG JING"，其他内容不变，具体情况如下： 一、《药品生产许可证》的主要信息 企业名称：陕西康惠制药股份有限公司 许可证编号：陕 20160073 社会信用代码：916100006984144239 分类码：AhzCz 注册地址：陕西省咸阳市秦都区高新技术产业开发区彩虹二路 法定代表人：李红明 陕西康惠制药股份有限公司 关于变更药品生产许可证的公告 生产负责人：郭建刚 有效期至：2030 年 8 月 24 日 生产地址和生产范围： 陕西省咸阳市秦都区高新技术产业开发区胭脂路 36 号：膏药，软膏剂，茶 剂，颗粒剂，硬胶囊剂，片剂，酒剂，合剂，搽剂，酊剂，洗剂； 陕西省咸阳市秦都区高新开发区 ...

Company Overview - Kanghui Co., Ltd. is located in Xi'an, Shaanxi Province, established on December 24, 2009, and listed on April 21, 2017. The company is primarily engaged in the research, development, production, and sales of traditional Chinese medicine [1][2] - The main business revenue composition includes: pharmaceutical manufacturing 60.68%, pharmaceutical distribution 36.79%, and others 2.53% [1] Stock Performance - As of October 31, Kanghui's stock price increased by 2.00%, reaching 22.40 CNY per share, with a total market capitalization of 2.237 billion CNY [1] - Year-to-date, the stock price has risen by 55.99%, but it has seen a decline of 2.01% over the last five trading days, 0.18% over the last 20 days, and 0.13% over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" five times this year, with the most recent appearance on June 16, where it recorded a net purchase of 7.7 million CNY [1] Financial Performance - For the period from January to September 2025, Kanghui reported a revenue of 356 million CNY, a year-on-year decrease of 11.97%, and a net profit attributable to shareholders of -133 million CNY, a significant year-on-year decrease of 246.07% [2] - The company has cumulatively distributed 54.2348 million CNY since its A-share listing, with no distributions made in the last three years [3] Shareholder Information - As of September 30, the number of shareholders for Kanghui was 9,458, a decrease of 21.15% from the previous period, while the average circulating shares per person increased by 26.82% to 10,560 shares [2] Industry Classification - Kanghui is classified under the pharmaceutical and biological industry, specifically in the traditional Chinese medicine sector, and is associated with concepts such as Helicobacter pylori, pharmaceutical e-commerce, hepatitis treatment, traditional Chinese medicine, and NMN [2]

Core Viewpoint - Kanghui Co., Ltd. is a well-known Chinese traditional Chinese medicine enterprise with strong technical capabilities in drug research and production, facing challenges in revenue and profitability compared to industry peers [1][2]. Group 1: Company Overview - Kanghui Co., Ltd. was established on December 24, 2009, and listed on the Shanghai Stock Exchange on April 21, 2017, with its registered and office locations in Xi'an, Shaanxi Province [1]. - The company engages in the research, development, production, and sales of traditional Chinese medicine, classified under the pharmaceutical and biological industry [1]. Group 2: Financial Performance - For Q3 2025, Kanghui's revenue was 356 million yuan, ranking 60th out of 69 companies in the industry, while the industry leader, Baiyunshan, reported revenue of 61.606 billion yuan [2]. - The company's net profit for the same period was -157 million yuan, placing it 66th in the industry, with the top performer, Yunnan Baiyao, achieving a net profit of 4.789 billion yuan [2]. Group 3: Financial Ratios - As of Q3 2025, Kanghui's debt-to-asset ratio was 60.48%, an increase from 51.46% in the previous year, significantly higher than the industry average of 32.81% [3]. - The gross profit margin for Q3 2025 was 26.45%, down from 32.15% year-on-year, and below the industry average of 52.44% [3]. Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 21.15% to 9,458, while the average number of circulating A-shares held per shareholder increased by 26.82% to 10,600 [5].

Core Viewpoint - The company is undergoing significant changes, including a capital increase for its wholly-owned subsidiary, Beijing Kanghui Zhichuang Technology Co., Ltd., and addressing financial challenges related to its subsidiary, Shaanxi Youbang Biomedical Technology Co., Ltd. [11][67] Financial Data - The company plans to increase the registered capital of Kanghui Zhichuang from 10 million RMB to 100 million RMB by investing 90 million RMB [11][13] - The financial data for the first three quarters of 2025 has been disclosed, with specific revenue categories and regional performance yet to be detailed [64][65] Corporate Governance - The sixth board of directors has completed its re-election, with changes in the controlling shareholder and actual controllers [5] - The board meeting held on October 29, 2025, approved the capital increase and other significant resolutions [24][28] Subsidiary Operations - Kanghui Zhichuang, established in May 2025, is in its early stages of business development and does not significantly impact the company's overall performance [11][15] - Shaanxi Youbang has ceased operations and is seeking bankruptcy reorganization due to its inability to repay debts, which poses a risk to the company's financial health [67][69] Investment and Risk Management - The company is taking steps to enhance the financial strength of its subsidiaries while managing risks associated with potential losses from Shaanxi Youbang [18][75] - The company has recognized a bad debt provision of 120.9 million RMB related to Shaanxi Youbang, which will reduce its net profit for the first nine months of 2025 by 59.2 million RMB [60][62]

Core Viewpoint - Kanghui Co., Ltd. reported a decline in revenue and an increase in net loss for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company achieved an operating revenue of 356 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 11.97% [1] - The net profit attributable to shareholders of the parent company was -133 million yuan, which is a loss increase of 94.215 million yuan compared to the same period last year [1] - The basic earnings per share were -1.33 yuan [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 陕西康惠制药股份有限公司（以下简称"公司"）于 2025 年 10 月 29 日召开 第六届董事会第三次会议，审议通过了《关于对应收款项单项计提坏账准备的议 案》，现将相关事项公告如下： 一、本次对应收款项单项计提坏账准备的情况 证券代码：603139 证券简称：康惠股份 公告编号：2025-068 陕西康惠制药股份有限公司 关于对应收款项单项计提坏账准备的公告 四、本次计提减值损失的审批程序及意见 1、审计委员会意见 公司本次对应收款项单项计提坏账准备是基于谨慎性原则，符合《企业会计 准则》和公司会计制度的相关规定，能够更加公允地反映公司的财务状况和经营 成果，有利于为投资者提供更加真实可靠的会计信息，不存在损害公司和股东的 利益的情况。 2、董事会审议及意见 为解决控股子公司陕西友帮生物医药科技有限公司（以下简称"陕西友帮"） 资金短缺问题，促进其顺利投产并正常运营，自 2020 年 9 月以来，公司累计向 陕西友帮拆借资金 24,991.80 万元，主要用于生产设备的采购、 ...

证券代码：603139 证券简称：康惠股份 公告编号：2025-072 陕西康惠制药股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 11 月 04 日(星期二)至 11 月 10 日(星期一)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （ir@sxkh.com）进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 陕西康惠制药股份有限公司（以下简称"公司"）已于 2025 年 10 月 30 日发 布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 11 月 11 日（星期二） 16:00-17:00 通 过 上 海 证 券 交 易 所 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/）举办 2025 年第三季度业绩说明会，就投资者 关心的问题进行交流。 董事 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据上海证券交易所发布的上市公司分行业信息披露指引及《关于做好主板 上市公司 2025 年第三季度报告披露工作的重要提醒》相关要求，现将公司 2025 年前三季度主要经营数据披露如下： 一、报告期内，公司主营业务收入按分行业经营情况如下： 注：此表中收入类别的"其他"主要系全资子公司北京康惠智创科技有限公司的相关数 据，该子公司 2025 年 5 月设立，无上年数据。 二、报告期内，公司主营业务收入按产品用途经营情况如下： 证券代码：603139 证券简称：康惠股份 公告编号：2025-071 陕西康惠制药股份有限公司 关于2025年前三季度主要经营数据的公告 单位：万元 项 目 营业收入 营业成本 毛利率（%） 营业收入比上 年增减（%） 营业成本比上 年增减（%） 毛利率比上 年增减(%) 本公告之经营数据未经审计，提醒投资者审慎使用上述数据，注意投资风险。 陕西康惠制药股份有限公司董事会 2025 年 10 月 30 日 妇科类 2,494.58 1,165.74 53.2 ...

证券代码：603139 证券简称：康惠股份 公告编号：2025-069 陕西康惠制药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 陕西康惠制药股份有限公司（以下简称"公司"）控股子公司陕西友帮生 物医药科技有限公司（以下简称"陕西友帮"）拟以不能清偿到期债务且明显缺 乏清偿能力，但具有重整价值为由，向有管辖权的人民法院申请破产重整，并申 请启动预重整程序。 陕西友帮预重整程序尚待法院受理并裁定，能否进入预重整及重整程序 具有不确定性，公司将根据本次预重整及重整事项的进展情况及时履行信息披露 义务，敬请广大投资者注意投资风险。 一、事件概述 关于控股子公司陕西友帮拟申请预重整及重整的公告 公司控股子公司陕西友帮因全面停产，持续经营能力存在不确定性，且难以 清偿到期债务，故其拟向法院申请预重整及重整。2025 年 10 月 29 日，公司召 开第六届董事会第三次会议，以 9 票同意、0 票反对、0 票弃权，审议通过《关 于陕西友帮拟向法院申请预重整及重整的议案》，同意陕西友帮作为债务人向法 院申请重 ...